Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Policies & Guidelines
Filter by Topic
Best Practices
Clinical Guidelines
End-of-Life Care
Health Policy
NCCN 2015 Updates
NCCN Guidelines
Pathways
Patient Advocacy
Patient Navigation
Quality Care
Survivorship
Survivorship Care
Aggressive End-of-Life Care Continues to Be Offered to Younger Patients with Cancer
By
Phoebe Starr
End-of-Life Care
,
Value in Oncology
,
Policies & Guidelines
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Aggressive end-of-life care for patients with terminal cancer and other illnesses is costly and not recommended. ASCO recommends that patients with terminal cancer should receive palliative care rather than interventions that do not prolong life but do add to suffering.
Read Article
ASCO President Addresses Quality Care Through Collective Wisdom
By
Wayne Kuznar
Quality Care
,
Value in Oncology
,
Policies & Guidelines
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
In her presidential address, Julie M. Vose, MD, MBA, Chief of the Oncology/Hematology Division, University of Nebraska Medical Center, Omaha, highlighted the importance of multimodal care and its effect on the quality of care and enhancement of clinical trial participation among patients with cancer.
Read Article
FDA Advisors Vote Against Duchenne Muscular Dystrophy Drug, Reject Value of Hope for Patients
By
Robert Goldberg, PhD
Patient Advocacy
,
Policies & Guidelines
July 2016, Vol 7, No 6
On April 25, 2016, an FDA advisory committee voted not to recommend the approval of eteplirsen, an experimental drug that targets one of many genetic mutations causing Duchenne muscular dystrophy (DMD), a deadly degenerative disease that has no cure. After agreeing to study the real-world effects of eteplirsen, the FDA advisory committee rejected findings that patients who have been taking eteplirsen since 2011 were still able to walk because the clinical data did not meet the FDA requirements for a well-controlled study.
Read Article
FDA Streamlines Expanded Access Application for Patients to Get Investigational Drugs
By
Nick Bryant
Health Policy
,
Policies & Guidelines
July 2016, Vol 7, No 6
The Individual Patient Expanded Access Application, which is designed to streamline the application procedure for individual patients who apply for expanded access to investigational therapeutics, including expanded access to drugs that are not in clinical trials, was recently updated by the FDA. Form FDA 3926 authorizes expanded access to investigational drugs for patients with serious or life-threatening conditions who have no therapeutic options.
Read Article
Proposed Reductions to Medicare Drug Payments Will Hurt Patients, Small Practices
By
Jessica Miller
Health Policy
,
Policies & Guidelines
July 2016, Vol 7, No 6
Opposition to proposed changes to the Medicare Part B payment for prescription drugs continues to grow since the Centers for Medicare & Medicaid Services (CMS) announced its plan in March 2016.
Read Article
New Oncology Care Model Focuses on Payment Reform and Value-Based Care
By
Jessica Miller
Health Policy
,
Value-Based Care
,
Policies & Guidelines
July 2016, Vol 7, No 6
A new payment and delivery model introduced by the Center for Medicare & Medicaid Innovation aims to align financial incentives to improve oncology care and outcomes. Expected to begin in July 2016, the program will target patients from the start of their chemotherapy through 6 months of care.
Read Article
Decision Aids: Facilitating Communication with Cancer Survivors
By
Chase Doyle
Survivorship
,
Policies & Guidelines
May 2016, Vol 7, No 4
Linking physicians and patients is a major undertaking, but given the ubiquity of smartphone technology and the rise in app development, the healthcare industry is poised to leverage advances in communication and information exchange. At the 2016 Cancer Survivorship Symposium, Steven J. Katz, MD, MPH, Professor of Medicine and Health Management and Policy, University of Michigan, Ann Arbor, discussed the use of deliberation systems to enhance communication with survivors and their care.
Read Article
Multidisciplinary Teamwork Needed for Survivorship Care
By
Chase Doyle
Survivorship
,
Policies & Guidelines
May 2016, Vol 7, No 4
“When we talk about multidisciplinary cancer care teams, I think it is important to discuss MDT [multidisciplinary team] clinical decision-making,” said Dr Jacobs. “How does the team really work together?”
Read Article
Secondary Pathology Review May Improve Clinical Outcomes
By
Meg Barbor, MPH
Quality Care
,
Policies & Guidelines
May 2016, Vol 7, No 4
Secondary pathology review can significantly improve clinical outcomes through precise and accurate pathology diagnoses, according to Lavinia P. Middleton, MD, Professor, Department of Pathology, M.D. Anderson Cancer Center, Houston, TX.
Read Article
Web-Based Reporting Beneficial in Tracking Medication Occurrence
By
Meg Barbor, MPH
Quality Care
,
Policies & Guidelines
May 2016, Vol 7, No 4
Web-based reporting in the outpatient community setting is not only feasible, but it can identify areas that need quality improvement initiatives, according to J. Russell Hoverman, MD, PhD, Vice President of Quality Programs, Texas Oncology, PA, Dallas.
Read Article
Page 2 of 11
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma